Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study

Abstract

These findings indicate clinically relevant differences exist in the sexual side effect profiles of these selected antipsychotics. These factors should be considered when selecting the most appropriate treatment for outpatients with schizophrenia.

Relative association of treatment‐emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3‐year observational study

“…These findings are clinically relevant as clinicians may underrate the potential effects of common adverse events such as sexual dysfunction and extrapyramidal symptoms. Indeed, clinicians frequently underestimate the effect of treatment-emergent adverse events on a patient's quality of life (Dossenbach et al, 2006;Voruganti et al, 2000) even though it is apparent that there are clear differences in the underlying factors that influence patient-rated and clinician-rated quality of life (Fitzgerald et al, 2003). Overall, the findings from our study support the increasing recognition that incorporating patients' perceptions of their treatment, in particular their responses to adverse events, is a valuable component of patient management.…”

A study of the efficacy and safety of switching from oral risperidone to risperidone long-acting injection in older patients with schizophrenia

“…Hyperprolactinaemia is a factor that can result in sexual dysfunction, one of the primary causes of reduced QOL [Baggaley, 2008], and risperidoneinduced hyperprolactinaemia is dose dependent [Dossenbach et al 2006]. The results of this study suggest that, in older patients, switching from oral risperidone to RLAI, with the same reduction in the risperidone equivalent dose as in younger patients, may result in a significant reduction in prolactin levels compared with the control group who continued on oral risperidone.…”

Psychometric Properties of the Psychotropic-Related Sexual Dysfunction Questionnaire (PRSexDQ-SALSEX) in Patients with Schizophrenia and Other Psychotic Disorders

“…This side effect is among the most distressing to patients with schizophrenia (Weiden & Miller, 2001, Lambert et al, 2004, is associated with low satisfaction with the treatment (Fakhoury, Wright, & Wallace, 2001), and may impair treatment compliance (Weiden, Mackell, & McDonnell 2002), leading to the stoppage of their medication one or more times during treatment in over 40% of males and 15% of females (Rosenberg, Bleiberg, Koscis, & Gross, 2003). Unfortunately, this important side effect is frequently underestimated by psychiatrists (Dossenbach et al, 2006) and is rarely spontaneously reported by patients (Knegtering et al, 2004;Montejo Gonzalez, Rico-Villademoros, Tafalla, & Majadas, 2005;Knegtering et al, 2006). Therefore, the availability of a tool for evaluating sexual functioning would be very useful for surveying this side effect both in the clinical practice and in the research setting.…”